Brentuximab

Class: Antineoplastic Agents
Chemical Name: Complex with N-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-l-valyl-N5-(aminocarbonyl)-l-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-l-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-l-valinamide, dimer, disulfide with human-mouse monoclonal cAC10 k-chain, anti-(human CD30 (antigen)) (human-mouse monoclonal cAC10 γ1-chain), immunoglobulin G1
Molecular Formula: C₆₄₇₆H₉₉₃₀N₁₆₉₀O₂₀₃₀S₄₀ (C₆₈H₁₀₅N₁₁O₁₅)_n
CAS Number: 914088-09-8
Brands: Adcetris

Medically reviewed by Drugs.com on May 23, 2022. Written by ASHP.

Introduction

Antineoplastic agent; an anti-CD30 antibody conjugated with a microtubule inhibitor (monomethyl auristatin E [MMAE]).

Uses for Brentuximab

Hodgkin Lymphoma

Used in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of previously untreated stage III or IV classical Hodgkin lymphoma (cHL). Efficacy determined based on substantially reduced risk of progression, death, or, in those who did not achieve a complete response, receipt of subsequent anticancer therapy compared with combination therapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

Used as single agent consolidation therapy for cHL at high risk of relapse or progression following autologous stem cell transplantation. Efficacy determined based on substantially prolonged median progression-free survival compared with placebo.

Used as a single agent for the treatment of cHL following failure of autologous stem cell transplantation or following failure of ≥2 multiple-agent chemotherapy regimens in patients who are not candidates for autologous stem cell transplantation. Efficacy determined based on objective response rate in a noncomparative, open-label study in patients with relapsed Hodgkin lymphoma.

Designated an orphan drug by FDA for treatment of Hodgkin lymphoma.

Peripheral T-cell Lymphoma (PTCL)

Used in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-positive PTCL, including angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified (PTCL-NOS) (designated an orphan drug by FDA for treatment of these cancers ). Efficacy determined based on prolonged progression-free survival and overall survival compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP).

Used as a single agent for the treatment of sALCL following failure of ≥1 multiple-agent chemotherapy regimen (designated an orphan drug by FDA for treatment of this cancer ). Efficacy determined based on objective response rate in a noncomparative,...